source stringlengths 2 222 | date stringlengths 19 19 | url stringlengths 22 853 ⌀ | text stringlengths 0 10k ⌀ | title stringlengths 0 701 | context_id stringlengths 1 9 | document_id stringclasses 2
values | document_type stringclasses 2
values |
|---|---|---|---|---|---|---|---|
CNBC | 2022-02-02 12:21:54 | https://www.cnbc.com/2022/02/02/cramers-investing-club-were-encouraged-abbvie-shares-held-recent-gains-after-a-mixed-quarter.html | Despite some spotty results here and there, we saw strength in all the right places in AbbVie's fourth-quarter earnings report. | Cramer's Investing Club: We're encouraged AbbVie shares held recent gains after a mixed quarter | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
MarketBeat | 2022-02-02 11:32:12 | https://www.marketbeat.com/originals/high-yield-deep-value-abbvie-confirms-uptrend/?SNAPI | Shares of AbbVie (NYSE: ABBV) fell in the wake of the Q4 results because the results were a little mixed in relation to the analyst's estimates. That dip resulted in a buy signal for the broader market, however, because mixed as they were, the results are strong, the outlook is positive, the dividend is safe, and AbbVi... | High-Yield, Deep-Value AbbVie Confirms Uptrend | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2022-02-02 10:46:22 | https://www.zacks.com/stock/news/1861235/abbvie-abbv-tops-q4-earnings-estimates | AbbVie (ABBV) delivered earnings and revenue surprises of 0.61% and 0.94%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock? | AbbVie (ABBV) Tops Q4 Earnings Estimates | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Benzinga | 2022-02-02 10:34:41 | https://www.benzinga.com/general/biotech/22/02/25366289/abbvie-expects-solid-fy22-as-botox-skyrizi-power-q4-earnings | AbbVie Inc ABBV reports Q4 adjusted EPS of $3.31, higher than $2.92 reported a year ago and beating the consensus of $3.28. Thousands of new traders are learning the ins and outs on how to find profitable trades every day with Benzinga Trading School. | AbbVie Expects Solid FY22 As Botox, Skyrizi Power Q4 Earnings | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Market Watch | 2022-02-02 08:06:52 | https://www.marketwatch.com/story/abbvies-stock-gains-on-fourth-quarter-earnings-as-it-reports-better-than-expected-sales-of-humana-2022-02-02 | Shares of AbbVie Inc. ABBV, +0.08% gained 1.4% in premarket trading on Wednesday after the company beat earnings expectations and generated more sales than expected of its top-selling rheumatoid arthritis drug, Humira. AbbVie had earnings of $4.0 billion, or $2.26 per share, in the fourth quarter of 2021, compared with... | AbbVie's stock gains on fourth-quarter earnings as it reports better-than-expected sales of Humana | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Reuters | 2022-02-02 07:46:00 | https://www.reuters.com/business/healthcare-pharmaceuticals/abbvie-forecasts-2022-profit-above-estimates-strong-sales-botox-skyrizi-2022-02-02/ | AbbVie Inc forecast full-year adjusted profit above estimates on Wednesday, as its blockbuster anti-wrinkle injection Botox and newer psoriasis drug Skyrizi beat Wall Street expectations for quarterly sales. | AbbVie forecasts 2022 profit above estimates on strong sales of Botox, Skyrizi | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-02-01 11:45:00 | https://www.fool.com/investing/2022/02/01/is-abbvie-stock-a-buy-now/ | The pharma giant is tackling new competition for its blockbuster drug, but there remains more to do. | Is AbbVie Stock a Buy Now? | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2022-02-01 11:30:21 | https://www.zacks.com/stock/news/1860564/pharma-stocks-to-report-q4-earnings-on-feb-2-abbv-nvs-nvo | Let us take a look at three large pharma companies - ABBV, NVS and NVO - due to release their quarterly results on Feb 2. | Pharma Stocks to Report Q4 Earnings on Feb 2: ABBV, NVS & NVO | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2022-02-01 09:59:25 | https://www.zacks.com/stock/news/1860458/why-abbvie-abbv-might-surprise-this-earnings-season | AbbVie (ABBV) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season. | Why AbbVie (ABBV) Might Surprise This Earnings Season | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2022-02-01 00:02:43 | https://seekingalpha.com/article/4483085-abbvie-can-continue-generating-substantial-shareholder-returns | AbbVie Can Continue Generating Substantial Shareholder Returns | AbbVie Can Continue Generating Substantial Shareholder Returns | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
GuruFocus | 2022-01-31 16:48:21 | https://www.gurufocus.com/news/1629549/analysts-think-sales-of-abbvies-migraine-drugs-will-each-top-2-billion | Two new migraine treatments from AbbVie Inc. ( ABBV , Financial) could help offset any headaches caused by declining sales of the company's mega-blockbuster Humira. | Analysts Think Sales of AbbVie's Migraine Drugs Will Each Top $2 Billion | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
24/7 Wall Street | 2022-01-31 13:27:31 | https://247wallst.com/investing/2022/01/31/earnings-previews-abbvie-humana-marathon-petroleum-novartis/ | U.S. equity markets opened mixed on Monday, with the Dow Jones industrials lagging and the tech-heavy Nasdaq adding about 1.5% in the early going. | Earnings Previews: AbbVie, Humana, Marathon Petroleum, Novartis | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2022-01-31 12:20:09 | https://www.zacks.com/stock/news/1859943/abbvie-s-abbv-q4-earnings-may-reflect-slower-sales-recovery | AbbVie's (ABBV) drugs are expected to have continued the recovering trend in sales during the fourth quarter. However, increased COVID-19 cases are likely to have hurt the pace of recovery during the quarter. | AbbVie's (ABBV) Q4 Earnings May Reflect Slower Sales Recovery | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2022-01-31 08:10:00 | https://seekingalpha.com/article/4482494-blue-chip-you-cannot-afford-to-miss-yield-4-1-percent-abbvie | The upcoming loss of Humira exclusivity is a legitimate concern. However, robust sales of Rinvoq and Skyrizi are working to fill the gap. | 'Blue Chip' You Cannot Afford To Miss, Yield 4.1%: AbbVie | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-01-30 11:28:00 | https://www.fool.com/investing/2022/01/30/better-dividend-stock-abbvie-or-pfizer/ | One looks to have better growth prospects. | Better Dividend Stock: AbbVie or Pfizer? | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-01-29 05:58:00 | https://www.fool.com/investing/2022/01/29/can-abbvie-beat-pfizer-in-the-atopic-dermatitis-ma/ | Maybe. But neither is likely to knock Dupixent off its perch. | Can AbbVie Beat Pfizer in the Atopic Dermatitis Market? | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Invezz | 2022-01-28 17:04:55 | https://invezz.com/news/2022/01/28/mizuhos-vamil-divan-reveals-his-top-biotech-pick/ | AbbVie Inc (NYSE: ABBV) closed 2021 with a 25% gain in the stock price, and Mizuho's senior biopharmaceuticals research analyst says 2022 will be another year of outperformance for the biotech giant. Divan sees upside to $154 a share According to Vamil Divan, AbbVie is his top biotech pick, which he rates at “buy” with... | Mizuho's Vamil Divan reveals his top biotech pick | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2022-01-28 16:09:19 | https://www.zacks.com/commentary/1859303/value-growth-or-momentum-what-kind-of-investor-are-you | No matter what strategy you decide is best in 2022, always remember that investing is a personal journey. Your life, and where you see yourself in 10, 20, 30 years, should be the driving force behind your investing decisions and strategies. | Value, Growth, or Momentum: What Kind of Investor are You? | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2022-01-28 12:19:30 | https://www.zacks.com/stock/news/1859098/is-a-beat-likely-for-abbvie-abbv-this-earnings-season | AbbVie's (ABBV) fourth-quarter results are expected to reflect the impact of strong demand for immunology drugs, aesthetics and cosmetics. Investors are likely to focus on any update related to the guidance for 2022. | Is a Beat Likely for AbbVie (ABBV) This Earnings Season? | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
CNBC Television | 2022-01-27 18:10:16 | https://www.youtube.com/watch?v=sbKdPqxAF3s | "Halftime Report" trader Pete Najarian spots unusual activity in the options market | Pete's latest options plays | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2022-01-27 13:50:10 | https://www.zacks.com/stock/news/1858443/2-stocks-to-buy-during-market-turbulence-before-earnings | Diving into two strong stocks that also pay a dividend that investors might want to consider buying heading into earnings. | 2 Stocks to Buy During Market Turbulence Before Earnings | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2022-01-27 10:46:15 | https://www.zacks.com/stock/news/1858178/should-value-investors-pick-abbvie-abbv-at-present | Is AbbVie (ABBV) a great pick from the value investor's perspective right now? Read on to know more. | Should Value Investors Pick AbbVie (ABBV) At Present? | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2022-01-26 16:24:46 | https://seekingalpha.com/article/4481870-labu-a-compelling-biotech-trade | LABU - A Compelling Biotech Trade | LABU - A Compelling Biotech Trade | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-01-26 10:45:00 | https://www.fool.com/investing/2022/01/26/2-reasons-to-buy-abbvie-stock-and-1-reason-to-sell/ | This stock has a lot in its favor, but there's also a big near-term risk. | 2 Reasons to Buy AbbVie Stock, and 1 Reason to Sell | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2022-01-25 13:32:04 | https://seekingalpha.com/article/4481505-abbvie-skyrizis-and-rinvoq-latest-fda-approvals-bode-well-for-humira-patent-loss | Recent FDA approval for Skyrizi was obtained for the treatment of adults with active psoriatic arthritis. Another recent FDA approval was for Rinvoq, which was approved for the treatment of adults and children ages 12 and older for moderate to severe atopic dermatitis. | AbbVie: Skyrizi And Rinvoq Latest FDA Approvals Bode Well For Humira Patent Loss | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2022-01-25 12:56:31 | https://seekingalpha.com/article/4481482-vertex-investors-look-out-abbv-data-coming-soon | Vertex Investors Look Out...AbbVie Data In Cystic Fibrosis Coming Soon | Vertex Investors Look Out...AbbVie Data In Cystic Fibrosis Coming Soon | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2022-01-24 19:14:49 | https://www.zacks.com/stock/news/1856415/abbvie-abbv-gains-but-lags-market-what-you-should-know | AbbVie (ABBV) closed at $132.16 in the latest trading session, marking a +0.14% move from the prior day. | AbbVie (ABBV) Gains But Lags Market: What You Should Know | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2022-01-24 10:49:06 | https://www.zacks.com/stock/news/1856107/abbvie-s-abbv-skyrizi-gets-fda-nod-for-psoriatic-arthritis | AbbVie (ABBV) secures approval in the United States for Skyrizi to treat adult patients with active psoriatic arthritis. | AbbVie's (ABBV) Skyrizi Gets FDA Nod for Psoriatic Arthritis | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-01-24 08:00:00 | https://www.fool.com/investing/2022/01/24/3-no-brainer-healthcare-stocks-to-buy-right-now-fo/ | Not only is the price right for these three healthcare stocks, but they all offer revenue growth along with an above-average dividend. | 3 No-Brainer Healthcare Stocks to Buy Right Now for Less than $150 | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-01-24 06:10:00 | https://www.fool.com/investing/2022/01/24/these-high-yield-dividend-stocks-are-growing-at-bl/ | Investors willing to venture a little off the beaten path will find income and growth don't have to be mutually exclusive. | These High-Yield Dividend Stocks Are Growing at Blazing Speeds | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-01-23 06:12:00 | https://www.fool.com/investing/2022/01/23/is-abbvie-stock-a-top-pick-for-2022/ | Can this high-yielder help shore up your portfolio in an unstable market? | Is AbbVie Stock a Top Pick for 2022? | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-01-22 09:30:00 | https://www.fool.com/investing/2022/01/22/1-top-dividend-stock-to-buy-right-now/ | Dividends can provide a safe harbor in the market storm. | 1 Top Dividend Stock to Buy Right Now | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Stockmarketcom | 2022-01-20 22:07:39 | https://stockmarket.com/featured/top-biotech-stocks-to-buy-now-5-for-your-late-january-watchlist-2022-01-20 | Which biotech stocks are you watching today? | Top Biotech Stocks To Buy Now? 5 For Your Late January Watchlist | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2022-01-20 14:35:08 | https://www.zacks.com/stock/news/1854841/3-value-stocks-breaking-out-in-2022 | Not all stocks are selling off to start 2022. These cheap, top Zacks Ranked stocks are doing the opposite. | 3 Value Stocks Breaking out in 2022 | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
InvestorPlace | 2022-01-20 14:29:04 | https://investorplace.com/2022/01/3-dividend-aristocrats-yielding-over-4/ | When looking for great dividend stocks, one of the best places to start is with the Dividend Aristocrats. These companies have stood the test of time and economic weakness, and in the case of Leggett & Platt, AbbVie and Chevron, they all have current yields that are more than triple that of the S&P 500. | 3 Dividend Aristocrats Yielding Over 4% | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
InvestorPlace | 2022-01-19 11:54:28 | https://investorplace.com/2022/01/3-healthcare-stocks-ignoring-the-market-mayhem/ | Sellers dominate the Street this week, but some healthcare stocks remain unaffected. Here are three to put atop your watchlist. | 3 Healthcare Stocks Ignoring the Market Mayhem | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
InvestorPlace | 2022-01-19 06:00:09 | https://investorplace.com/2022/01/3-dividend-stocks-to-buy-and-hold-forever-abbv-kr-cvx/ | Investors wanting dividends to fortify their portfolio should consider dividend stocks that deliver outsized payments to shareholders. The post 3 Dividend Stocks to Buy and Hold Forever appeared first on InvestorPlace. | 3 Dividend Stocks to Buy and Hold Forever | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
InvestorPlace | 2022-01-18 14:27:13 | https://investorplace.com/2022/01/7-of-the-top-rated-pharmaceutical-stocks-for-q1/ | As the market begins to shift from high-growth, tech-fueled start-ups, one good long-term growth option is quality pharmaceutical stocks. The post 7 of the Top-Rated Pharmaceutical Stocks for Q1 appeared first on InvestorPlace. | 7 of the Top-Rated Pharmaceutical Stocks for Q1 | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Benzinga | 2022-01-18 06:33:21 | https://www.benzinga.com/general/biotech/22/01/25079545/fda-gives-back-to-back-approval-to-pfizers-abbvies-jak-inhibitors-for-atopic-dermatitis | Along with AbbVie Inc's (NYSE: ABBV) upadacitinib approval, the FDA approved Pfizer Inc's (NYSE: PFE) oral daily JAK1 inhibitor Cibinqo (abrocitinib) to treat adults with moderate to severe atopic dermatitis. The approval covers patients who have not been able to get their disease under control with other medicines, in... | FDA Gives Back To Back Approval To Pfizer's & AbbVie's JAK Inhibitors For Atopic Dermatitis | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Benzinga | 2022-01-18 05:10:59 | https://www.benzinga.com/general/biotech/22/01/25079022/fda-approves-abbvies-upadacitinib-for-refractory-atopic-dermatitis-in-patients-12-years-older | The FDA has approved AbbVie Inc's (NYSE: ABBV) Rinvoq (upadacitinib) for atopic dermatitis in adults and children 12 years of age and older. The approval covers moderate to severe atopic dermatitis in patients whose disease did not respond to previous treatment, not well controlled with other pills or injections, or wh... | FDA Approves AbbVie's Upadacitinib For Refractory Atopic Dermatitis In Patients 12 Years & Older | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2022-01-17 19:15:35 | https://www.zacks.com/stock/news/1853048/abbvie-abbv-outpaces-stock-market-gains-what-you-should-know | In the latest trading session, AbbVie (ABBV) closed at $135.87, marking a +1.76% move from the previous day. | AbbVie (ABBV) Outpaces Stock Market Gains: What You Should Know | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2022-01-17 12:24:06 | https://www.zacks.com/stock/news/1852860/abbvie-s-abbv-rinvoq-gets-fda-nod-for-atopic-dermatitis | FDA approves AbbVie's (ABBV) Rinvoq for the treatment of moderate to severe atopic dermatitis in adults and children aged 12 and above. This is the third indication for Rinvoq in the United States. | AbbVie's (ABBV) Rinvoq Gets FDA Nod for Atopic Dermatitis | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2022-01-17 10:00:23 | https://www.zacks.com/commentary/1852556/4-large-cap-drugmaker-stocks-to-watch-despite-omicron-woes | Drug/biotech and medical device companies are likely to remain in the spotlight in 2022. Among the large drugmakers Roche (RHHBY), Pfizer (PFE), AbbVie (ABBV), and Merck (MRK) are worth retaining in your portfolio. | 4 Large-Cap Drugmaker Stocks to Watch Despite Omicron Woes | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-01-17 06:07:00 | https://www.fool.com/investing/2022/01/17/is-abbvie-a-good-dividend-stock-to-buy-right-now/ | This pharmaceutical stock has delivered steadily growing dividend payouts in the past, and investors want to know if it can keep the pace. | Is AbbVie a Good Dividend Stock to Buy Right Now? | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-01-16 11:31:00 | https://www.fool.com/investing/2022/01/16/3-pharma-stocks-with-especially-juicy-dividends/ | These drugmakers should have no problems keeping the dividends flowing -- and growing. | 3 Pharma Stocks With Especially Juicy Dividends | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2022-01-16 05:01:24 | https://seekingalpha.com/article/4479862-january-buffett-dividend-dogs-show-three-dandy-dynamutts | January Buffett Dividend Dogs Show 3 Dandy Dynamutts | January Buffett Dividend Dogs Show 3 Dandy Dynamutts | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2022-01-15 09:07:31 | https://seekingalpha.com/article/4479814-abbvie-abbv-stock-keep-going-higher | AbbVie continues to be under-appreciated and undervalued. The company's revenue, EPS, and dividend arc all consistent growers. | AbbVie Will Keep Going Higher | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-01-13 06:15:00 | https://www.fool.com/investing/2022/01/13/4-top-dividend-payers-of-the-sp-500/ | These stocks could one day be paying dividends of 7% or higher. | 4 Top Dividend Payers of the S&P 500 | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2022-01-13 06:07:00 | https://seekingalpha.com/article/4479462-sdy-etf-looking-higher-yields-dividend-growth-stocks | SDY: Looking For Higher Yields In Dividend Growth Stocks | SDY: Looking For Higher Yields In Dividend Growth Stocks | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-01-12 08:30:00 | https://www.fool.com/investing/2022/01/12/2-monster-stocks-to-buy-for-2022-that-are-practica/ | These fundamentally strong companies with robust cash flows can prove to be attractive picks in 2022. | 2 Monster Stocks to Buy for 2022 That Are Practically Minting Money | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2022-01-11 22:44:03 | https://seekingalpha.com/article/4479162-abbvie-inc-abbv-management-presents-jpmorgan-40th-annual-healthcare-conference-transcript | AbbVie Inc. (ABBV) Management Presents at JPMorgan 40th Annual Healthcare Conference (Transcript) | AbbVie Inc. (ABBV) Management Presents at JPMorgan 40th Annual Healthcare Conference (Transcript) | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2022-01-10 22:42:59 | https://seekingalpha.com/article/4478901-abbvie-record-price-doesnt-change-our-bull-thesis-according-to-buffetts-rule | This is an update to my previous bullish thesis on AbbVie Inc. published on August 8, 2021. Since then, the price has climbed up by ~17% and you may be wondering if it is time to take profit and sell. | AbbVie: Does Record Price Change Our Bull Thesis? No According To Buffett's Rule | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2022-01-10 19:09:27 | https://www.zacks.com/stock/news/1849904/abbvie-abbv-gains-as-market-dips-what-you-should-know | AbbVie (ABBV) closed at $136.39 in the latest trading session, marking a +1.12% move from the prior day. | AbbVie (ABBV) Gains As Market Dips: What You Should Know | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
CNBC Television | 2022-01-10 14:08:22 | https://www.youtube.com/watch?v=lhdR1BoWyvI | The "Halftime Report" traders give their top picks to watch for the second half. | Final Trades: Goldman Sachs, Abbvie, Merck & more | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2022-01-10 07:42:03 | https://www.zacks.com/stock/news/1849410/abbvie-abbv-seeks-rinvoq-nod-for-non-radiographic-as | AbbVie's (ABBV) application seeking approval of Rinvoq for nr-axSpA was based on data from the phase III SELECT-AXIS 2 (Study 2) study. | AbbVie (ABBV) Seeks Rinvoq Nod for Non-Radiographic AS | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-01-09 09:27:00 | https://www.fool.com/investing/2022/01/09/3-no-brainer-big-pharma-stocks-to-buy-in-2022/ | There's a lot to like about each of these companies. | 3 No-Brainer Big Pharma Stocks to Buy in 2022 | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
GuruFocus | 2022-01-07 14:30:03 | https://www.gurufocus.com/news/1611521/3-dividend-aristocrats-with-marketbeating-yields | The Dividend Aristocrats are a good place to find high-quality companies offering long track record of dividend growth. To be a member of this group, a company must have at least 25 consecutive years of dividend growth and be a member of the S&P 500 Index. | 3 Dividend Aristocrats With Market-Beating Yields | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Schaeffers Research | 2022-01-07 10:23:40 | https://www.schaeffersresearch.com/content/bgs/2022/01/07/the-worst-stock-to-buy-this-january | As we say welcome in the New Year with cautious optimism, it's important to note not just the best stock picks to bet on, but also the ones to avoid. | The Worst Stock to Buy This January | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2022-01-06 22:32:58 | https://seekingalpha.com/article/4478357-10-upcoming-dividend-increases-including-the-abbotts | All stocks have at least five fiscal years of dividend growth history and come from the U.S. Dividend Champions List. They have an average increase of 7.1% and a median increase of 7.2%. I've tracked 21 increases in 2022. | 10 Upcoming Dividend Increases Including The 'Abbotts' | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2022-01-06 12:16:06 | https://www.zacks.com/stock/news/1848424/4-reasons-why-you-should-add-abbvie-abbv-to-your-portfolio | AbbVie (ABBV) has several new drugs with the potential to drive revenues once Humira loses U.S. exclusivity in 2023. Its early and mid-stage pipeline has several candidates with blockbuster potential. | 4 Reasons Why You Should Add AbbVie (ABBV) to Your Portfolio | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2022-01-06 12:16:04 | https://www.zacks.com/commentary/1848420/how-to-select-stocks-during-volatile-market-periods | How to Select Stocks During Volatile Market Periods | How to Select Stocks During Volatile Market Periods | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2022-01-06 11:52:25 | https://seekingalpha.com/article/4478243-abbvie-doing-the-right-thing | Aside of performance and volatility, proper diversification and proper allocation/s are crucial. Don't bet too much on anything, no matter how "sexy" it may look. RIG's largest position has a 5.2% allocation and it's up 16.5% over the past six weeks (since inception date). | AbbVie: Doing The RIG(HT) Thing | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2022-01-05 13:49:03 | https://www.zacks.com/stock/news/1847983/abbvie-abbv-is-an-incredible-growth-stock-3-reasons-why | AbbVie (ABBV) is well positioned to outperform the market, as it exhibits above-average growth in financials. | AbbVie (ABBV) is an Incredible Growth Stock: 3 Reasons Why | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
GuruFocus | 2022-01-05 12:01:43 | https://www.gurufocus.com/news/1609540/these-emerging-biotechs-could-beat-alzheimers-disease | The Alzheimer's Disease treatment market is known for its vast potential given the fact that there are hardly any active drugs and therapies that produce any real improvements in patients' conditions. | These Emerging Biotechs Could Beat Alzheimer's Disease | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2022-01-05 10:45:21 | https://www.zacks.com/stock/news/1847705/abbvie-abbv-gets-fda-breakthrough-tag-for-lung-cancer-drug | AbbVie's (ABBV) Breakthrough Therapy Designation for Teliso-V is based on data from the phase II LUMINOSITY study. | AbbVie (ABBV) Gets FDA Breakthrough Tag for Lung Cancer Drug | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2022-01-05 09:30:00 | https://seekingalpha.com/article/4477928-upcoming-ex-dividend-dates-january-6-17-2022 | We provide a summary of upcoming ex-dividend dates in a quick reference table. The table includes relevant data and key statistics as well as the next payout and pay date. | Upcoming Ex-Dividend Dates: January 6-17, 2022 | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-01-04 06:15:00 | https://www.fool.com/investing/2022/01/04/this-big-pharma-stock-is-enriching-shareholders-wi/ | Bristol Myers Squibb is rewarding its shareholders with a huge dividend hike and a massive share-buyback program. | This Big Pharma Stock Is Enriching Shareholders With Its Dividend. But Is It a Buy? | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2022-01-03 19:07:33 | https://www.zacks.com/stock/news/1846683/abbvie-abbv-gains-but-lags-market-what-you-should-know | In the latest trading session, AbbVie (ABBV) closed at $135.42, marking a +0.01% move from the previous day. | AbbVie (ABBV) Gains But Lags Market: What You Should Know | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2022-01-03 14:10:15 | https://seekingalpha.com/article/4477732-best-dividend-stocks-january-2022 | We start out with a short list of guidelines that make it easier to identify dividend stocks that are still worth investing in right now. | The Best Dividend Stocks For January 2022 | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2022-01-03 05:27:01 | https://seekingalpha.com/article/4477651-abbvie-abbv-dividend-investor-pick | AbbVie once again reported strong quarterly results with revenue growing in the double digits. But analysts are rather pessimistic that AbbVie will not be able to grow with a similar pace as in the last few years. | AbbVie: A Pick For Dividend Investors With A 4.2% Yield | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-01-02 06:20:00 | https://www.fool.com/investing/2022/01/02/could-this-fda-approval-create-a-blockbuster-drug/ | Immunology medicine Rinvoq was green-lit to treat patients with psoriatic arthritis in the U.S. | Could This FDA Approval Create a Blockbuster Drug for AbbVie? | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-12-30 22:20:00 | https://seekingalpha.com/article/4477308-near-perfect-portfolio-for-bull-markets-and-bear-markets | No portfolio or strategy can be perfect. But can there be a strategy that can work well in a bull market, a bear market, or a stagnant market, generate a decent income, and conserve capital, all at the same time? We also want our strategy to avoid roller-coaster rides of index investing, have low volatility and limited... | The Near-Perfect Portfolio For The Bull Markets And The Bear Markets | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Stockmarketcom | 2021-12-30 17:00:00 | https://stockmarket.com/featured/5-dividend-stocks-to-watch-in-2022-2021-12-30 | Could these dividend stocks be big winners in the new year? | 5 Dividend Stocks To Watch In 2022 | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
InvestorPlace | 2021-12-30 14:42:41 | https://investorplace.com/2021/12/best-stocks-for-2022-why-abbvie-abbv-stock-looks-like-high-dividend-growth-stock/ | A solid year and an excellent third-quarter report from AbbVie has ABBV stock look like it is one of the best stocks to buy for 2022. The post Best Stocks for 2022: Why AbbVie Looks Like High Dividend Growth Stock appeared first on InvestorPlace. | Best Stocks for 2022: Why AbbVie Looks Like High Dividend Growth Stock | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
CNBC Television | 2021-12-30 14:25:38 | https://www.youtube.com/watch?v=e0wZxrzA4FA | "Halftime Report" trader Jon Najarian spots unusual activity in the options market. | Bullish call buying in AbbVie | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2021-12-30 07:00:00 | https://www.fool.com/investing/2021/12/30/3-dividend-kings-that-are-yielding-more-than-3/ | You don't need to sacrifice a good yield for safety. | 3 Dividend Kings That Are Yielding More Than 3% | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-12-29 16:53:47 | https://seekingalpha.com/article/4477237-my-top-ten-stocks-for-2022 | This is the 22nd year I've published my top 10 stock picks. | My Top 10 Stocks For 2022 | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
24/7 Wall Street | 2021-12-29 07:26:17 | https://247wallst.com/investing/2021/12/29/5-high-yielding-dividend-aristocrats-are-strong-buy-stock-ideas-for-2022/ | It is hard to believe 2021 is all but over and 2022 is upon us. The Santa Claus rally has carried the S&P 500 back to new all-time highs and everything seems set up for a strong January. | 5 High-Yielding Dividend Aristocrats Are ‘Strong Buy' Stock Ideas for 2022 | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-12-28 20:35:53 | https://seekingalpha.com/article/4477146-abbvie-warren-buffett-favorite-high-yield-dividend-retire-rich | AbbVie is Warren Buffett's favorite high-yield aristocrat and for good reason. AbbVie's management team is in the top 17% of pharma when it comes to risk management, and its execution on its post-Humira plan has been nearly flawless. | AbbVie: 2 Ways Buffett's Favorite High-Yield Dividend Aristocrat Can Help You Retire Rich | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2021-12-28 06:27:00 | https://www.fool.com/investing/2021/12/28/what-abbvies-recent-drug-news-means-for-shareholde/ | AbbVie's immunology drug Skyrizi could soon be approved in the European Union to treat patients with Crohn's disease. | What AbbVie's Recent Drug News Means for Shareholders | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
GuruFocus | 2021-12-27 12:03:47 | https://www.gurufocus.com/news/1603968/3-highyield-stocks-for-dividend-investors | Dividend investors could be interested in the following stocks, since they offer much higher dividend yields than the S&P 500 Index. The dividend of the benchmark index yields 1.25% as of the close of trading on Thursday. | 3 High-Yield Stocks for Dividend Investors | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-12-26 11:59:59 | https://seekingalpha.com/article/4476842-top-dividend-aristocrats-tag-four-to-buy-for-january | "Dividend Aristocrats in the S&P 500 Index have raised their annual payouts every year for at least 25 consecutive years." - Kiplinger. The 65 Aristocrats screened as of December 23, 2021, represented all eleven Morningstar Sectors. Broker targeted-top-ten net-gainers ranged 14.59%-32.89% topped by MDT and LEG. | Top Dividend Aristocrats Tag 4 To Buy For January | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2021-12-26 06:55:00 | https://www.fool.com/investing/2021/12/26/3-dividend-stocks-to-buy-if-market-crashes-2022/ | The next crash is always around the corner, so get ready. | 3 Dividend Stocks to Buy If the Market Crashes in 2022 | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2021-12-24 08:08:00 | https://www.fool.com/investing/2021/12/24/3-best-buffett-stocks-to-buy-for-the-long-haul/ | Each of these three big pharma stocks are featured in Berkshire Hathaway's massive portfolio. | 3 Best Buffett Stocks to Buy for the Long Haul | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-12-23 05:00:00 | https://seekingalpha.com/article/4476533-abbvie-rinvoq-approval-merry-christmas-all-around | FDA's approval of Rinvoq in treatment of psoriatic arthritis releases it from the FDA's JAK inhibitor penalty box. AbbVie's 12/2021 Rinvoq approval for psoriatric arthritis has created a a pathway for additional Rinvoq wins. | AbbVie's Merry Christmas All Around | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2021-12-22 19:07:38 | https://www.zacks.com/stock/news/1842512/abbvie-abbv-outpaces-stock-market-gains-what-you-should-know | AbbVie (ABBV) closed the most recent trading day at $132.05, moving +1.62% from the previous trading session. | AbbVie (ABBV) Outpaces Stock Market Gains: What You Should Know | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
InvestorPlace | 2021-12-22 06:00:21 | https://investorplace.com/2021/12/3-of-the-best-biotech-stocks-for-2022-to-buy-now/ | These three biotech stocks have performed amazingly well of late and are more than likely to perform even better next year. The post 3 of the Best Biotech Stocks for 2022 to Buy Now appeared first on InvestorPlace. | 3 of the Best Biotech Stocks for 2022 to Buy Now | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2021-12-21 07:45:00 | https://www.fool.com/investing/2021/12/21/better-buy-viatris-vs-abbvie/ | Both face headwinds -- and future opportunities. | Better Buy: Viatris vs. AbbVie | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
CNBC Television | 2021-12-20 13:57:44 | https://www.youtube.com/watch?v=0re6g2n2QYo | The "Halftime Report" traders give their top picks to watch for the second half. For access to live and exclusive video from CNBC subscribe to CNBC PRO: https://cnb.cx/2NGeIvi » Subscribe to CNBC TV: https://cnb.cx/SubscribeCNBCtelevision » Subscribe to CNBC: https://cnb.cx/SubscribeCNBC Turn to CNBC TV for the latest... | Final Trades: AbbVie, Discovery, the XLF & more | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-12-19 01:26:34 | https://seekingalpha.com/article/4475886-buffett-december-dividend-dogs-display-4-dandy-dynomutts | This Buffett holdings list from Kiplinger first appeared 9/16/21 online. YCharts and Dogs of The Dow also track this Buffett/Berkshire Batch. Here is your update from 12/15/21 YCharts data. 28 of 43 current Berkshire-Hathaway-owned-stocks pay dividends. As of 12/15/21, the top ten ranged 2.39%-5.06% by annual-yield and... | Buffett's December Dividend Dogs Display 4 Dandy Dynomutts | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2021-12-18 07:09:00 | https://www.fool.com/investing/2021/12/18/3-reasons-why-this-healthcare-stock-is-a-long-term/ | Two of them might generate revenue growth, but the third is the bonus all investors should love. | 3 Reasons Why This Healthcare Stock Is a Long-Term Buy | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2021-12-18 06:55:00 | https://www.fool.com/investing/2021/12/18/what-to-make-of-the-fdas-latest-warning-to-abbvie/ | There's still a worst-case scenario that the FDA could unleash. | What to Make of the FDA's Latest Warning to AbbVie and Pfizer | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2021-12-16 19:08:16 | https://www.zacks.com/stock/news/1840345/abbvie-abbv-gains-as-market-dips-what-you-should-know | AbbVie (ABBV) closed the most recent trading day at $131.78, moving +1.19% from the previous trading session. | AbbVie (ABBV) Gains As Market Dips: What You Should Know | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Stockmarketcom | 2021-12-16 18:51:20 | https://stockmarket.com/featured/5-biotech-stocks-for-your-late-december-2021-watchlist-2021-12-16 | Should investors be treating these top biotech stocks as top picks in the stock market now? | 5 Biotech Stocks For Your Late December 2021 Watchlist | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2021-12-16 11:45:00 | https://www.fool.com/investing/2021/12/16/unstoppable-dividend-king-2022-abbvie-or-johnson-a/ | Both of these two healthcare stocks have potential. Which one has a better year ahead? | Unstoppable Dividend King for 2022: AbbVie or Johnson & Johnson? | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Pulse2 | 2021-12-15 21:34:35 | https://pulse2.com/abbvie-stock-nyse-abbv-why-the-price-increased/ | The stock price of AbbVie Inc (NYSE: ABBV) increased by 2.31% today. This is why it happened. | AbbVie Stock (ABBV): Why The Price Increased | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2021-12-15 12:20:19 | https://www.zacks.com/stock/news/1839698/abbvie-abbv-rinvoq-gets-fda-nod-for-active-psoriatic-arthritis | The FDA approves AbbVie's (ABBV) Rinvoq for the treatment of adults with active psoriatic arthritis. This is the second FDA-approved indication for the drug. | AbbVie (ABBV) Rinvoq Gets FDA Nod for Active Psoriatic Arthritis | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Stockmarketcom | 2021-12-15 10:08:27 | https://stockmarket.com/featured/5-top-healthcare-dividend-stocks-to-watch-today-2021-12-15 | Should investors consider these healthcare dividend stocks amid the current market volatility? | 5 Top Healthcare Dividend Stocks To Watch Today | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-12-15 00:34:27 | https://seekingalpha.com/article/4475281-santa-is-delivering-10-high-yield-dividend-aristocrat-bargains-you-wont-want-to-miss | Santa Is Delivering 10 High-Yield Dividend Aristocrat Bargains You Won't Want To Miss | Santa Is Delivering 10 High-Yield Dividend Aristocrat Bargains You Won't Want To Miss | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2021-12-14 13:47:00 | https://seekingalpha.com/article/4475193-dividend-income-summary-berts-november-2021-report | Dividend investing in 2021 is as important as ever. The market has been on fire for the year, and dividend stocks continue to flex their muscles and grow at insane rates. I invest in dividend stocks to grow my passive income. | Dividend Income Summary: Bert's November 2021 Report | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.